Transform Wealth LLC Makes New Investment in Pfizer Inc. (NYSE:PFE)

Posted by on Mar 23rd, 2023

Transform Wealth LLC acquired a new stake in Pfizer Inc. (NYSE:PFE – Get Rating) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 5,455 shares of the biopharmaceutical company’s stock, valued at approximately $280,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Lam Group Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $25,000. Karp Capital Management Corp bought a new position in Pfizer during the third quarter worth $27,000. Worth Asset Management LLC bought a new position in Pfizer during the first quarter worth $29,000. My Personal CFO LLC bought a new position in Pfizer during the fourth quarter worth $32,000. Finally, Delos Wealth Advisors LLC boosted its position in Pfizer by 100.0% during the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 400 shares during the period. 67.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 target price on shares of Pfizer in a research report on Wednesday, February 1st. StockNews.com initiated coverage on Pfizer in a research note on Thursday, March 16th. They set a “buy” rating for the company. Morgan Stanley reduced their price target on Pfizer from $53.00 to $45.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 1st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and set a $51.00 price target on the stock in a report on Tuesday, February 7th. Finally, JPMorgan Chase & Co. set a $45.00 target price on Pfizer in a report on Monday, February 27th. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $50.38.

Pfizer Stock Performance

NYSE:PFE opened at $40.01 on Thursday. The business’s 50-day moving average price is $42.82 and its two-hundred day moving average price is $45.92. Pfizer Inc. has a twelve month low of $39.23 and a twelve month high of $56.32. The stock has a market cap of $225.83 billion, a P/E ratio of 7.30, a PEG ratio of 1.37 and a beta of 0.64. The company has a quick ratio of 1.00, a current ratio of 1.22 and a debt-to-equity ratio of 0.34.

Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.11. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The firm had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. During the same quarter last year, the firm posted $1.08 EPS. The company’s revenue was up 1.9% compared to the same quarter last year. As a group, equities analysts predict that Pfizer Inc. will post 3.3 EPS for the current fiscal year.

Insider Buying and Selling at Pfizer

In other Pfizer news, major shareholder Pfizer Inc purchased 1,811,594 shares of the stock in a transaction on Friday, March 17th. The shares were purchased at an average price of $2.76 per share, with a total value of $4,999,999.44. Following the acquisition, the insider now directly owns 5,952,263 shares in the company, valued at approximately $16,428,245.88. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.05% of the company’s stock.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.